摘要
目的探究支气管哮喘患者行布地奈德福莫特罗与孟鲁司特联合治疗的临床效果及安全性。方法选取2016年8月~2018年8月期间我院收治的80例支气管哮喘疾病患者为研究对象,以患者入院时间先后顺序进行分组,其中包括对照组40例及观察组40例。对照组患者行布地奈德福莫特罗治疗,观察组患者基于布地奈德福莫特罗给药孟鲁司特,应用统计学软件对两组患者治疗前后肺功能指标,临床症状消退时间,给药后不良反应等指标进行比较。结果治疗前两组患者肺功能指标差异无统计学意义(P>0.05),治疗后两组患者肺功能指标水平相比治疗前均有明显,其中观察组患者提升幅度更明显,且咳嗽、喘息等临床症状消退时间均明显少于对照组,差异有统计学意义(P<0.05);两组患者药物不良反应差异无统计学意义(P>0.05)。结论支气管哮喘患者临床治疗中实施布地奈德福莫特罗与孟鲁司特联合给药方案效果理想,且安全性较高,能够有效改善患者肺功能,对患者康复具有积极影响,因此值得在临床中进行大力推广。
Objective To explore the clinical curative effects and safety of budesonide formoterol combined with montelukast in treatment of patients with bronchial asthma. Methods 80 patients with bronchial asthma who were admitted and treated in our hospital from August 2016 to August 2018 were selected as research objects.According to the time of admission,they were divided into the control group and the observation group,with 40 cases in each group. The control group was treated with budesonide formoterol while the observation group was treated with montelukast based on budesonide formoterol.Pulmonary function indexes,regression time of clinical symptoms and adverse reactions were compared between the two groups before and after treatment with statistical software. Results There was no significant difference in pulmonary function indexes between the two groups before treatment (P > 0.05).After treatment,the pulmonary function indexes of the two groups were significantly higher than those before treatment,and the increase in the observation group was more significant.Regression time of clinical symptoms such as cough and wheezing was significantly lower than that of the control group,and the difference was statistically significant (P < 0.05).There was no statistically significant difference in adverse drug reactions between the two groups (P > 0.05). Conclusion Budesonide formoterol combined with montelukast in clinical treatment of patients with bronchial asthma has ideal curative effects and high safety.It can effectively improve the lung function of patients,which has a positive effect on the rehabilitation of patients.Therefore,it is worthy of wide promotion in clinical practice.
作者
马杰生
郑瑞如
连晓玲
MA Jiesheng;ZHENG Ruiru;LIAN Xiaoling(Department of Respiratory Medicine,Chaonan Minsheng Hospital,Guangdong,Shantou 515100,China)
出处
《中国医药科学》
2019年第15期233-235,共3页
China Medicine And Pharmacy
关键词
布地奈德福莫特罗
孟鲁司特
支气管哮喘
肺功能
不良反应
Budesonide formoterol
Montelukast
Bronchial asthma
Pulmonary function
Adverse reactions